Developing autoantibody signatures to predict disease recurrence and immune-related adverse events in patients receiving adjuvant immunotherapy
18 Jun 2024
Salon B
Immune Biomarkers
![Developing autoantibody signatures to predict disease recurrence and immune-related adverse events in patients receiving adjuvant immunotherapy](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/experts/CDI-Labs.png/fit-in/1500x9999/filters:no_upscale())
- Do autoantibody signatures / biomarkers offer advantages over DNA, RNA and protein
- biomarkers?
- Can autoantibody profiles be used as a tool for treatment monitoring?
- What are the best approaches for identifying autoantibody signatures?
- What are the preferred platforms for discovering and validating autoantibody signatures?
Industry Expert